Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for ADC-Induced Thrombocytopenia in Solid Tumors
ChiCTR2600130622Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of recombinant human thrombopoietin in Thrombocytopenia and Nonhematologic neoplasms (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Proportion of patients who can effectively maintain platelet counts at the end of the second treatment cycle. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
ThrombocytopeniaNonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2600130622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130622.